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onto the bronchial stump only. Therefore, we modified our
technique for dealing with the residual space, either by oblit-
erating the space with concomitant limited thoracoplasty or
by covering the raw surface with the latissimus dorsi (muscle
tent).6 During the last 4 1/2 years of this series, we did not
encounter space problems in any patients.
Postoperative chemotherapy is as indispensable as pre-
operative chemotherapy. The purpose of resectional surgery
is to remove the main lesions that harbor numerous organ-
isms. This means that scattered nodular lesions and tiny cav-
ities may be left behind. In this study, approximately 3/4 of
patients had some degree of lesions in the lungs on the oppo-
site side. Hence, it is crucial to keep patients on multidrug
regimens for a sufficiently long period in order to hold the
bacilli at bay in these lesions. Our duration of postoperative
chemotherapy is 2 years, either when patients have positive
sputum at the time of surgery or when they have positive
specimen culture results. We may shorten the duration of
chemotherapy, provided that patients have achieved sputum
conversion prior to surgery and have negative specimen cul-
ture results. However, the optimal duration of postoperative
chemotherapy requires further investigation.
Our study includes several distinctive features. First, as we
are affiliated with the Japan Anti-Tuberculosis Association,
our institution is one of the most experienced centers for
the treatment of multidrug-resistant tuberculosis in Japan.
We have such a reliable laboratory that we can routinely
perform drug susceptibility testing on first- and second-
line drugs and levofloxacin. As we have all types of anti-
tuberculosis drugs on hand, we can create the best available
multi-drug regimens that are individualized for each patient.
Nevertheless, favorable results with adjuvant resectional
surgery have been reported not only from developed coun-
tries, but also from developing countries where medical
resources are limited.13,14
Second, we preferred to use gatifloxacin late in this series
in expectation of its potent efficacy against tuberculosis
bacilli.15 Gatifloxacin has, however, been currently with-
drawn from sale both in the United States and in Japan be-
cause of the increased risk of dysglycemia in humans.
This necessitates alternate, newer fluoroquinolones. As we
live in an era in which extensively drug-resistant tuberculo-
sis exists, multidrug-resistant tuberculosis should be con-
trolled by any means. An aggressive treatment approach to
multidrug-resistant tuberculosis continues to be justified un-
til a panacea for this refractory disease is available.
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Dr Alain Chapelier (Suresnes, France). Dr Shiraishi and col-
leagues reported their updated experience of patients with
multidrug-resistant Mycobacterium tuberculosis (MDR-TB) who
underwent adjuvant resectional surgery with no mortality and
excellent outcome. Dr Shiraishi has to be congratulated for these
results in a technically challenging group of patients and for his
nice presentation.
Surgery was considered for the patients with persistent positive
sputum and the patients with a high risk of relapse because of resid-
ual cavitary lesions. Among this latter group, a positive bacterial
examination of specimen was observed in approximately one third
of patients who were preoperatively culture-negative, and this is
a strong argument for surgery.
In this series, resections were performedwith extended use of the
latissimus dorsi muscle flap to reinforce the bronchial stump, as it
has been also recommended by others. You outline a significant re-
duction of postoperative complications in the recent period of your
experience. No residual pleural space problem was observed in the
late period of your study.
I have 3 questions. My first question is related to the additional
thoracoplasty. In the situation of a large post-resection space after
an upper lobectomy, extended or not to the upper segment of the
lower lobe, would you now advocate it systematically?
Dr Shiraishi (Tokyo, Japan). Yes, I would. In our series, we
found that space problems often occurred after we performeddiovascular Surgery c Volume 138, Number 5 1183
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To prevent the residual space, we have to close the residual space
by concomitant limited thoracoplasty or a muscle tent. I think the
important thing is that at first we put the latissimus dorsi just
onto the bronchial stump, but in that case we found that the raw sur-
face of the remaining lung was exposed to the pleural cavity and
might cause a minor leak and result in residual space. So I think
we have to remove some of the ribs to reduce the space and cover
the raw surface of the lung with muscle flap.
Dr Chapelier. My second question is concerning the patients
with bilateral lesions. Many of your patients had small nodular le-
sions in the contralateral lung at the time of preoperative assess-
ment. In 2 patients, however, you performed a planned staged
bilateral resection. Could you comment on your strategy for these
patients?
Dr Shiraishi. The best candidate for surgical therapy was the
patient who had limited lesions, for example, a cavity just in the
right upper lobe or left upper lobe, but some patients had cavities
in both lungs. In that case, if the patient had good pulmonary func-
tion and a cavity was just localized in both sides of the upper lobes,
we were able to remove both lesions, so we performed planned
staged bilateral resections. Also, if the cavity is very small (eg, 5
or 6 mm), maybe we can leave those lesions.
DrChapelier. Finally, your institution is clearly a referral center
for the treatment of MDR-TB in Japan, and you point out in the ar-
ticle the extreme importance of your laboratory to assess the effi-
cacy of all drugs preoperatively and postoperatively. Considering
the incidence of MDR-TB in the population of west European
countries, for example, the prevalence of newly diagnosed cases
is 1.4% in France with a stability during the last 10 years, and
with regard to the medical and surgical expertise required to reach
the results you reported today, would you recommend that this
combined treatment be done in only 1 or 2 centers in our countries?
Dr Shiraishi. I don’t understand your question.
Dr Chapelier.Do you think these difficult cases have to be done
in selected centers?
Dr Shiraishi. Oh, yes. Surgery should be done in very special-
ized and highly experienced centers.
Dr Chapelier. Thank you.
Dr Marvin Pomerantz (Aurora, Colo). I enjoyed your article.
Your results parallel our series published in the Journal of 180 re-
sections in 174 patients, which was in 2001. I have 2 questions.
Two of 3 of your pneumonectomies were on the left side. Every se-
ries I have ever read shows that if you do a pneumonectomy for tu-
berculosis, it is more often on the left side. Why is that?
Dr Shiraishi. Some groups have termed it ‘‘left lung syn-
drome’’ in such patients with tuberculosis. The left lung has1184 The Journal of Thoracic and Cardiovascular Sursome anatomic characteristics. The left main bronchus is longer
than the right main bronchus. That means more vulnerability to tu-
berculosis bacilli. So that’s why a left-sided pneumonectomy is
more often done than a right-sided pneumonectomy.
Dr Pomerantz.Well, I’m not sure that’s right. I’m not sure what
the answer is either, but it’s possibly due to the upper and lower
lobe bronchial takeoff being so close together. That’s another op-
tion. No one has been able to give me a good explanation. You
have a higher number of segmental resections than we had in our
series. I always thought it was better to make a wider resection
than just a segmental. We had several, but not the higher percent-
ages you have.
Dr Shiraishi. We performed a segmentectomy only in patients
with very tiny cavities or tiny nodular lesions. We usually do lobec-
tomy because the cavity is bigger. So in our series, the patients who
had a segmentectomy had very limited lesions.
Dr Pomerantz. My final question is, you had 2 bronchopleural
fistulas. Were they in patients who had positive sputum at the time
of surgery, and were they on the right side or the left?
Dr Shiraishi. If I recall correctly, one bronchopleural fistula oc-
curred on the right side after pneumonectomy. The other broncho-
pleural fistula occurred after left upper lobectomy. Both patients
had positive sputum at the time of surgery and comorbidities,
such as diabetes. Those patients had bronchopleural fistula 1 or 2
years after surgery, and the bronchial stump was eroded by the re-
lapse of multidrug-resistant strains, and that caused bronchopleural
fistula.
Dr Nasser Altorki (New York, NY). I want to ask you a little bit
about the segmentectomy. Are you advocating that patients with
MDR-TB have a lobectomy even if anatomically a segment can
be performed?
Dr Shiraishi. It depends on the patient’s pulmonary functional
reserve.
Dr Altorki. Assuming that the pulmonary examination allows
you to do either of these operations, is a segmentectomy sufficient
if you can get rid of gross disease, or do you have microscopic dis-
ease that requires a lobectomy be preferred?
Dr Shiraishi. We performed segmentectomy mostly on the left
upper division or lingular. In patients with limited lesions, we can
take whole lesions by performing a segmentectomy, not a lobec-
tomy.
Dr Altorki. I ask because the seminal work by Churchill and
Belsey described segmentectomy exactly in patients with tubercu-
losis, and I wonder if the fact that they have drug-resistant tubercu-
losis changes the treatment at all.
Dr Shiraishi. No, it won’t.
Dr Altorki. Thank you for your answer.gery c November 2009
